Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

By Brian Buntz | June 30, 2022

Pfizer logoThe voluntary Net-Zero Standard asks organizations to reduce emissions to near-zero levels by 2050 and neutralize any residual emissions.

Pfizer (NYSE:PFE) has announced its intent to meet that benchmark by 2040.

Pfizer intends to reduce its Greenhouse Gas (GHG) emissions by 95% and its value chain emissions by 90% from 2019 levels by 2040. To reach that goal, the company plans to reduce its reliance on fossil fuels and work with similarly-minded suppliers. It also plans to invest in a fleet of hybrid and electric vehicles.

The Net-Zero Standard was first announced by the Science-Based Targets initiative (SBTi).

Other pharma companies that have vowed to comply with the standard include AstraZeneca (LON:AZN), Bayer (OTCMKTS:BAYRY), Biogen (Nasdaq:BIIB), GSK (NYSE:GSK), Johnson & Johnson (NYSE:JNJ), Novartis (NYSE:NVS) and Sanofi (EPA:SAN).

Pfizer notes that its work to comply with the standard is part of its Environmental, Social and Governance (ESG) priorities.

Pfizer also announced that it had signed a voluntary U.S. Department of Health & Human Services (HHS) commitment to cut GHG emissions and accelerate climate action.

In 2020, Pfizer unveiled an initiative to become carbon neutral across internal operations by 2030.

“The window is closing to minimize the potentially catastrophic impact of climate change, which affects the health of our planet and that of people around the world,” said Pfizer CEO Albert Bourla in a news release. “With urgency of action increasing, we firmly believe that our commitment to accelerate decarbonization of our value chain and achieve the Net-Zero standard – which aligns with Pfizer’s purpose and ESG priorities – can help drive positive change and build a healthier, more sustainable world.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

GSK
GSK finalizes Affinivax acquisition 
vaccine
U.S. government makes an additional 442,000 monkeypox vaccine doses available 
Biogen logo
Biogen is scaling back space outside Boston
Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards